HealthyDirect · GrowthFit for a long SIP
Helios Mid Cap Fund
Helios Mutual FundEquity Schemes - Mid Cap Fund1.6 years
The scheme seeks to generate long-term capital ap preciation from a portfolio that is invested predominantly in equity and equity related securities of mid cap companies.
- NAV
- 13.20
- 30 Oct 2026
- 1Y
- +0.9%
- Trailing CAGR
- Upside capture
- +119%
- Vs NIFTY MIDCAP 150 TRI
- Downside capture
- +82%
- Lower is better
Buying brief
Should you add this fund?
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 30 Oct 2026
Stance
Fit for a long SIP
Evidence supports keeping this on a shortlist for a multi-year equity SIP.
In three lines
Fits if · The fund beat the category median in 95% of rolling 1-year windows.
Fits if · Risk-adjusted return sits above the documented risk-free proxy.
Buy checklist
History depth
Fail
1.6 years - thin for judging consistency.
Engine status
Pass
Evidence supports keeping this on a shortlist for a multi-year equity SIP.
Expense ratio
Pass
0.93% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Pass
Peak-to-trough -16.7%. Ask whether you can hold through a similar fall.
Vs category
n/a
Category relative read still thin.
Manager tenure
Watch
Alok Bahl · 1.7 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 24.8% of the portfolio.
Evidence supports a shortlist - confirm with peers before you buy elsewhere.
Before you buy or SIP
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 17%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
If you start a SIP here, diary a 90-day check and an annual review - don’t react to every NAV print.
NAV
Path not in current snapshots
n/a
Returns
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
- 1Y+0.9%
- 3Yn/a
- 5Yn/a
- 10Yn/a
- SI+18.2%
SIP XIRR
Equal monthly instalments to latest NAV
- 1Y+4.3%
- 3Yn/a
- 5Yn/a
- 10Yn/a
- Since inception
- +18.2%
- Calendar-day CAGR
- Excess 1Y
- +1.1%
- Category median, same plan and option
- 3Y win rate
- n/a
- Windows beating the median
- 3Y percentile
- n/a
- Vs comparable share classes
- SIP 3Y XIRR
- n/a
- Simulated monthly SIP
- Worst rolling 3Y
- n/a
- 0 daily-ending windows
- Median rolling 3Y
- n/a
- Calendar-day CAGR
- Positive rolling 5Y
- n/a
- 0 daily-ending windows
Official benchmark
Date-aligned against NIFTY MIDCAP 150 TRI. Capture ratios use common month-end observations through 30 Oct 2026.
- 1Y excess
- +5.3%
- Fund minus TRI
- 3Y excess
- n/a
- Fund minus TRI
- Upside capture
- +119%
- Benchmark-up months
- Downside capture
- +82%
- Lower is better
Drawdown
Peak to trough from a running NAV high, with the path and recovery episodes.
- Max drawdown
- -16.7%
- Worst peak-to-trough
- Current
- -8.5%
- Below last peak
- Current spell
- 63 days
- Days below latest peak
- Time below peak
- +78%
- NAV observations
Drawdown
Path not in current snapshots
n/a
- Average recovery
- 6 days
- 32 recovered episodes
- Longest recovery
- 45 days
- Trough to prior peak
17 Nov 2025 – 7 May 2026
Trough 23 Mar 2026 · recovered in 45 days
-16.7%
28 Aug 2026 – open
Trough 23 Oct 2026 · not recovered
-11.9%
24 Mar 2025 – 16 Apr 2025
Trough 7 Apr 2025 · recovered in 9 days
-5.4%
27 May 2026 – 15 Jun 2026
Trough 11 Jun 2026 · recovered in 4 days
-3.4%
Dimensions
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
24
Vs category
57
Consistency
95
Risk-adjusted
63
Drawdown
58
Mean
60
Decision
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Healthy
Buying stance
Fit for a long SIP
Evidence supports keeping this on a shortlist for a multi-year equity SIP.
Why this status
- No material deterioration, cost shock, or persistent category underperformance in the current evidence set.
Supporting reads
- The fund beat the category median in 95% of rolling 1-year windows.
- Risk-adjusted return sits above the documented risk-free proxy.
Portfolio
30 Sept 2026 · 76 holdings · top 10 are 24.8%.
- Top 5
- 13.8%
- Top 10
- 24.8%
- Largest holding
- 3.5%
- Effective holdings
- 60.6
One 97 Communications Ltd
Industrials
3.5%
Apar Industries Ltd
Diversified
2.8%
Coforge Ltd
Technology
2.7%
Phoenix Mills Ltd
Real Estate
2.6%
Sona BLW Precision Forgings Ltd
Consumer Discretionary
2.4%
What changed
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
21 Oct 2026
Worth investigating
Same-category peers with enough history to inspect beside this fund - including tradeoffs.
WhiteOak Capital Mid Cap Fund
WhiteOak Capital Mutual Fund
- 1Y
- +3.6%
- 3Y
- +20.4%
- Vol
- 14.8%
- Max DD
- -19.3%
- Sharpe
- 0.98
- 3Y win
- +100%
- Lower volatility
- Higher win rate vs category
- Higher trailing returns
Caveat: Deeper drawdown
BANDHAN MID CAP FUND
Bandhan Mutual Fund
- 1Y
- +3.3%
- 3Y
- +17.3%
- Vol
- 15.0%
- Max DD
- -22.7%
- Sharpe
- 0.74
- 3Y win
- +6%
- Lower volatility
- Lower TER
- Higher trailing returns
Caveat: Deeper drawdown
Canara Robeco Mid Cap Fund
Canara Robeco Mutual Fund
- 1Y
- -2.4%
- 3Y
- +15.4%
- Vol
- 15.1%
- Max DD
- -21.2%
- Sharpe
- 0.71
- 3Y win
- 0%
- Lower volatility
- Lower TER
- Higher trailing returns
Caveat: Deeper drawdown
HSBC Midcap Fund
HSBC Mutual Fund
- 1Y
- +9.6%
- 3Y
- +21.6%
- Vol
- 17.2%
- Max DD
- -26.0%
- Sharpe
- 0.91
- 3Y win
- +100%
- Higher win rate vs category
- Higher trailing returns
Caveat: Higher volatility · Deeper drawdown · Higher TER
Invesco India Mid Cap Fund
Invesco Mutual Fund
- 1Y
- -0.1%
- 3Y
- +22.0%
- Vol
- 16.2%
- Max DD
- -34.1%
- Sharpe
- 0.88
- 3Y win
- +52%
- Lower volatility
- Lower TER
- Higher trailing returns
Caveat: Deeper drawdown